Zenas crashes as late-stage trial data for lead asset disappoint
Source: SeekingAlpha
2026-01-05 09:17:10 ET
More on Zenas BioPharma, Inc.
- Zenas Prepares For INDIGO Phase 3 Readout - Reinstating Buy Rating
- Zenas BioPharma: Two Late-Stage Catalysts And A $2B InnoCare Deal
- Best Quant-rated small- and mid-cap healthcare stocks as LLY hits $1T in market cap
- Zenas BioPharma rises after Wedbush raises price target
- Seeking Alpha’s Quant Rating on Zenas BioPharma, Inc.
Read the full article on Seeking Alpha
For further details see:
Zenas crashes as late-stage trial data for lead asset disappoint
ProShares UltraPro Short NASDAQ Biotechnology
NASDAQ: ZBIO
ZBIO Trading
-3.26% G/L:
$24.06 Last:
166,899 Volume:
$24.93 Open:
ZBIO Latest News
ZBIO Stock Data
$1,157,322,819
29,738,258
0.79%
29
N/A
Biotechnology & Life Sciences
Healthcare
US
Waltham
